VGLL3 | |||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
Aliases | VGLL3, VGL-3, VGL3, Vestigial-like family member 3, vestigial like family member 3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
External IDs | OMIM: 609980 MGI: 1920819 HomoloGene: 53442 GeneCards: VGLL3 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
|
Vestigial-like family member 3 is a protein that in humans is encoded by the VGLL3 gene.[5]
See also
References
- 1 2 3 GRCh38: Ensembl release 89: ENSG00000206538 - Ensembl, May 2017
- 1 2 3 GRCm38: Ensembl release 89: ENSMUSG00000091243 - Ensembl, May 2017
- ↑ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ↑ "Entrez Gene: Vestigial-like family member 3".
Further reading
- Tao S, Wang Z, Feng J, Hsu FC, Jin G, Kim ST, Zhang Z, Gronberg H, Zheng LS, Isaacs WB, Xu J, Sun J (March 2012). "A genome-wide search for loci interacting with known prostate cancer risk-associated genetic variants". Carcinogenesis. 33 (3): 598–603. doi:10.1093/carcin/bgr316. PMC 3291863. PMID 22219177.
- Gambaro K, Quinn MC, Wojnarowicz PM, Arcand SL, de Ladurantaye M, Barrès V, Ripeau JS, Killary AM, Davis EC, Lavoie J, Provencher DM, Mes-Masson AM, Chevrette M, Tonin PN (June 2013). "VGLL3 expression is associated with a tumor suppressor phenotype in epithelial ovarian cancer". Molecular Oncology. 7 (3): 513–30. doi:10.1016/j.molonc.2012.12.006. PMC 5528482. PMID 23415753.
- Zhou W, Chen H, Zhang L (March 2009). "The PcG protein hPc2 interacts with the N-terminus of histone demethylase JARID1B and acts as a transcriptional co-repressor" (PDF). BMB Reports. 42 (3): 154–9. doi:10.5483/bmbrep.2009.42.3.154. PMID 19336002.
- Halperin DS, Pan C, Lusis AJ, Tontonoz P (February 2013). "Vestigial-like 3 is an inhibitor of adipocyte differentiation". Journal of Lipid Research. 54 (2): 473–81. doi:10.1194/jlr.M032755. PMC 3541706. PMID 23152581.
- Hélias-Rodzewicz Z, Pérot G, Chibon F, Ferreira C, Lagarde P, Terrier P, Coindre JM, Aurias A (December 2010). "YAP1 and VGLL3, encoding two cofactors of TEAD transcription factors, are amplified and overexpressed in a subset of soft tissue sarcomas". Genes, Chromosomes & Cancer. 49 (12): 1161–71. doi:10.1002/gcc.20825. PMID 20842732. S2CID 205828045.
- Wang L, Lu W, Chen YG, Zhou XM, Gu JR (December 1999). "Comparison of gene expression between normal colon mucosa and colon carcinoma by means of messenger RNA differential display". World Journal of Gastroenterology. 5 (6): 533–534. doi:10.3748/wjg.v5.i6.533. PMC 4688801. PMID 11819507.
- Maeda T, Chapman DL, Stewart AF (December 2002). "Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation". The Journal of Biological Chemistry. 277 (50): 48889–98. doi:10.1074/jbc.M206858200. PMID 12376544.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.